Patents Assigned to GUANGZHOU RIBOBIO CO., LTD.
  • Modified oligonucleotides and compound that can be used for synthesizing same
    Patent number: 11485752
    Abstract: The present disclosure falls within the field of biomedical technology, and in particular relates to modified oligonucleotides and a compound that can be used for synthesizing same and a method for modifying oligonucleotides. The present disclosure also relates to the use of the modified oligonucleotides for preventing and/or treating diseases associated with the liver in a subject.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: November 1, 2022
    Assignee: GUANGZHOU RIBOBIO CO., LTD.
    Inventors: Biliang Zhang, Wei Wang
  • Compositions and methods for inhibiting expression of ADAMTS-5 and ADAM17
    Patent number: 10709729
    Abstract: Provided are siRNAs or chemically-modified siRNAs targeted against ADAMTS-5 or ADAM17 for inhibiting the expression of ADAMTS-5 or ADAM17. Use of the siRNAs for treating an ADAMTS-5 or ADAM17 associated disease, such as arthritis and other inflammation-related diseases, by injecting the siRNAs or preparations comprising the siRNAs into an articular cavity of the patient, are also provided.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: July 14, 2020
    Assignees: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES, GUANGZHOU RIBOBIO CO., LTD.
    Inventors: Bill Biliang Zhang, Micky Daniel Tortorella, Zhe Wang, Xiuqun Yang, Qiuyun Wang